Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.exelixis.com
Exelixis, Inc. News Releases
Get the latest updates from Exelixis, Inc. News Releases directly as they happen.
Follow now 107 followers
Latest posts
Last updated 10 days ago
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
10 days ago
– Zanzalintinib in combination with atezolizumab demonstrated a statistically significant reduction in...
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
13 days ago
– A regulatory decision by the European Medicines Agency is anticipated in...
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
about 1 month ago
– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
about 1 month ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May...
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
about 2 months ago
- Total Revenues of $555.4 million , Cabozantinib Franchise U.S. Net Product...
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
about 2 months ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--May...
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
2 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
3 months ago
– FDA approval based on the phase 3 CABINET pivotal trial, which...
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
3 months ago
– Presentations will highlight best- and/or first-in-class potential of four small molecule...
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
4 months ago
-- Presentations to be webcast on www.exelixis.com -- ALAMEDA, Calif. --(BUSINESS WIRE)--Feb...
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
4 months ago
- Completion of currently ongoing stock repurchase program expected in the second...
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
5 months ago
– After more than five years of follow-up, CABOMETYX in combination with...